OBJECTIVE:To probe into the economic-effectiveness of different therapeutic schemes in the treatment of lower respiratory tract infections(LRTI).METHODS:86cases of LRTI were randomly divided into 2 groups:Group A received intravenous cefuroxime sodium while Group B received intravenous cefuroxime sodium and oral cefuroxime axetil sequential therapy.Cost-effectiveness of the 2 schemes was analyzed.RESULTS:The costs of the 2 therapeutic schemes were 677.60 yuan and 439.58 yuan(P0.05)respectively;the cost-effectiveness ratio of the 2 were 7.67 and 5.11 respectively.CONCLUSION:Scheme B was better than Scheme A in the treatment of lower respiratory tract infection.

OBJECTIVE:To evaluate the economic effectiveness of different pharmacotherapentic schemes of Prazoles for helicobacteria pylori (Hp) infection. METHODS: 102 patietns with peptic ulcer were randomly assigned to receive Omeprazole +amoxicillin + Colloidal bismmth pectin (Group A), Rabeprazole + Amoxicillin + Colloidal bismmth pectin (Group B) or Rebeprazole + amoxicillin + Colloidal bismmth pectin (Group C). The cost-effectiveness analysis was conducted on the three schemes. RESULTS: The cost-effectiveness ratios of groups A, B and C on Hp clearance rates were 1 027.31, 976.79 and 967.40, respectively, and on peptic ulcer healing rates were 921.05, 915.77 and 936.16, respectively. CONCLUSION: Scheme B is the best one for Hp infection.

OBJECTIVE:To evaluate the economic effectiveness of different pharmacotherapeutic schemes for peptic ulcer and chronic gastritis with infection of Helicobacteria pylori(Hp) METHODS:To perform cost-effectiveness analysis of three ther_apeutic schemes for Hp infection RESULTS:The cost-effectiveness ratios of three therapeutic schemes were 8 71,10 12 and 13 99 CONCLUSION:Scheme A(omeprazole+amoxicillin+clarithomycin) is the best one

ObjectiveTo construct the eukaryotic expression plasmids containing cysteine protease inhibitor (CPI) and glyceraldehydes-3-phosphate dehydrogenase (GAPDH) gene from periodic Brugia malayi (Bm),and to observe its cellular immune response in mouse.Methods pcDNA3.1 (+)-BmCPI/BmGAPDH was constructed.The recombinant plasmids were screened and identified by digestion with restriction enzyme.BALB/c mice were injected intramuscularly with a dosage of 100 μg purified recombinant plasmid DNA with GpG oligodeoxynucleotide (CpG ODN) and two same doses were administrated at 2-week intervals.pcDNA3.1 (+) and phosphate buffered solution (PBS) were used as controls.The tissue of muscles at 4 weeks after the third injection was collected and the target gene was detected by reverse transcription-polymerase chain reaction (RTPCR).Two weeks after the third immunization,the stimulation index (SI) of spleen lymphocytes of immunized mice was measured by methylthiazolyldiphenyl-tetrazolium bromide (MTT) method and the serum levels of interleukin (IL)-4 and interferon (IFN)-γ were detected by enzyme-linked immunosorbent assay (ELISA).The data were analyzed by t test.ResultsBmCPI/BmGAPDH gene in the injected muscle of the immunized mice was detected by RT-PCR. At 6 weeks after immunization,the SIot spleen T lymphocytes in pcDNA3.1 (+)-BmCPI/CpG group and pcDNA3.1 (+)-BmCPI/BmGAPDH/CpG group were 1.466 ± 0.635 and 1.610 ± 0.112,respectively,which were both higher than PBS group and pcDNA3.1( +)-CpG group (1.004 ± 0.019 and 1.078 ± 0.129,respectively) (t=64.438,45.318,42.749 and 34.314,respectively; all P＜0.05).At 4 weeks after immunization,the serum levels of IL-4 and IFN-γ of mice in pcDNA3.1 ( + )-BmCPI/BmGAPDH/ CpG group were significantly higher than those in pcDNA3.1 (+)-CpG group (t=288.053 and 76.453,respectively; both P＜0.05),while the serum level of IFN-γ was also higher than that in pcDNA3.1 (+)-BmCPI/CpG group (t=129.642,P＜0.05). ConclusionThe recombinant eukaryotic plasmid pcDNA3.1 (+)-BmCPI/BmGAPDH could be expressed in mice,and could elicit specific cellular immune responses in immunized mice.